Pharmacological characterization of losartan as a CCR2 antagonist and pre-clinical and pharmacodynamic assessment as a potential anti-metastatic therapy

Regan, Daniel P., authorDow, Steven, advisorSchenkel, Alan, committee memberThamm, Douglas, committee memberSlansky, Jill, committee memberBasaraba, Randall, committee member2017-09-142018-09-122017https://hdl.handle.net/10217/183925To view the abstract, please see the full text of the document.born digitaldoctoral dissertationsengCopyright and other restrictions may apply. User is responsible for compliance with all applicable laws. For information about copyright law, please see https://libguides.colostate.edu/copyright.CCL2dogsmonocytesCCR2cancermetastasisPharmacological characterization of losartan as a CCR2 antagonist and pre-clinical and pharmacodynamic assessment as a potential anti-metastatic therapyText